2. Academic Validation
  3. Synthesis and biological evaluation of 3,5-diaryl-pyrazole derivatives as potential antiprostate cancer agents

Synthesis and biological evaluation of 3,5-diaryl-pyrazole derivatives as potential antiprostate cancer agents

  • Arch Pharm (Weinheim). 2021 Dec;354(12):e2100225. doi: 10.1002/ardp.202100225.
Derya Anil 1,  Emine U Caykoylu 2,  Fatma Sanli 3 4,  Nicola Gambacorta 5,  Omer F Karatas 3 4,  Orazio Nicolotti 5,  Oztekin Algul 6 7,  Serdar Burmaoglu 2
Affiliations

Affiliations

  • 1 Department of Chemistry and Chemical Process Technologies, Erzurum Technical Science Vocational School, Atatürk University, Erzurum, Turkey.
  • 2 Department of Chemistry, Faculty of Science, Atatürk University, Erzurum, Turkey.
  • 3 Department of Molecular Biology and Genetics, Erzurum Technical University, Erzurum, Turkey.
  • 4 Molecular Cancer Biology Laboratory, High Technology Application and Research Center, Erzurum Technical University, Erzurum, Turkey.
  • 5 Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari "Aldo Moro", Bari, Italy.
  • 6 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Mersin University, Mersin, Turkey.
  • 7 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Erzincan Binali Yildirim University, Erzincan, Turkey.
PMID: 34467575 DOI: 10.1002/ardp.202100225
Abstract

Prostate Cancer is the most frequently diagnosed tumor in men and the second leading cause of cancer-associated mortality in most developed countries. 3,5-Diaryl substituted pyrazole derivatives (20-28) were prepared starting from related Chalcones and biologically evaluated for in vitro growth inhibition activity against PC3 and DU145 human prostate Cancer cell lines. Compounds 23, 26, and 28 were found to be more potent as compared to the Other halogen-substituted derivatives. Especially, the 2-bromo-substituted pyrazole derivative (26) was found to be more potent against PC3 and DU145 cells. Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor 2 (VEGFR2/KDR/Flk-1) are known to be expressed in DU145 and PC3 Cancer cells. The binding mode of the most selective compound 26 toward EGFR and VEGFR2/KDR/Flk-1 was investigated by employing docking simulations based on GLIDE standard precision (-5.912 and -6.949 kcal/mol, respectively).

Keywords

Claisen-Schmidt; molecular docking; prostate cancer; pyrazole; structure-activity relationships.

Figures
Products